OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Brown on the Benefits of Minimally Invasive Surgery in Ovarian Cancer

February 17th 2022

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

Dr. Burger on the Changing Treatment Landscape of CLL

February 17th 2022

Jan A. Burger, MD, PhD, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Dr. Choi on the Addition of Ublituximab to Ibrutinib in R/R CLL

February 16th 2022

Michael Choi, MD, discusses the results of the phase 3 GENUINE trial examining ublituximab in combination with ibrutinib vs ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Palmbos on the Utilization of Nivolumab Following Cystectomy in Muscle-Invasive Bladder Cancer

February 16th 2022

Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.

Dr. Tewari on the Factors to Consider for Robotic Radical Prostatectomy in Prostate Cancer

February 16th 2022

Ashutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy for a patient with prostate cancer.

Dr. Munver on the Utilization of Mitomycin Gel in GU Cancers

February 14th 2022

Ravi Munver, MD, discusses the utilization of mitomycin gel in genitourinary cancers.

Dr. Wang on the Evolution of Ibrutinib in the Treatment Landscape of MCL

February 14th 2022

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

Dr. Sharifi on Methodologies Utilized to Evaluate Link Between Gut Microbiome and Fatal Prostate Cancer

February 14th 2022

Nima Sharifi, MD, director, discusses the methodologies utilized when evaluating the correlation between gut microbiome and fatal prostate cancer.

Dr. Ku on the Efficacy of Zanidatamab Plus Chemotherapy in HER2+ Gastroesophageal Adenocarcinoma

February 11th 2022

Geoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.

Dr. McKean on the Importance of Molecular Profiling in Metastatic Melanoma

February 11th 2022

Meredith McKean, MD, MPH, discusses the importance of molecular profiling in melanoma.

Dr. Mesa on the Importance of Community Engagement for Optimal Care in Oncology

February 10th 2022

Ruben A. Mesa, MD, discusses the importance of community engagement to facilitate optimal care in oncology.

Dr. Sharifi on the Rationale to Evaluate the Correlation Between the Gut Microbiome and Aggressive Prostate Cancer

February 10th 2022

Nima Sharifi, MD, discusses the rationale to evaluate the correlation between the gut microbiome and the aggressiveness of prostate cancer.

Dr. Evens on the Design of a Retrospective Analysis Evaluating Salvage Regimens in R/R Hodgkin Lymphoma

February 10th 2022

Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.

Dr. Van Tine on the Methods Utilized in the Spearhead 1 Trial in Sarcoma Subtypes

February 10th 2022

Brian A. Van Tine, MD, PhD, discusses the methods utilized in the phase 2 Spearhead 1 trial evaluating afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Dr. Hill on the Potential Utility of Next-Generation PI3K Inhibitors in CLL

February 9th 2022

Brian T. Hill, MD, PhD, discusses the potential utility of next-generation PI3K inhibitors in chronic lymphocytic leukemia.

Dr. Woloszynska on the Role of Community Outreach in Addressing Disparities in Prostate Cancer

February 9th 2022

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

Dr. Wang on the Evolving Treatment Landscape of MCL

February 9th 2022

Michael Wang, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Dr. Bazhenova on Questions With Trastuzumab Deruxtecan in HER2-Mutated Lung Cancer

February 9th 2022

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

February 8th 2022

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Dr. Hales on the Role of Multidisciplinary Care in Locally Advanced Lung Cancer

February 7th 2022

Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.